SPOTLIGHT -
This roundtable series debates using newer JAK inhibitors as therapy for patients with myelofibrosis, considering the efficacy and safety profiles of the drugs, as discussed by participants at virtual live events.
Pacritinib Shows Tolerable Safety Profile for Thrombocytopenic Myelofibrosis
Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.
Data Shows How Ruxolitinib is the Cornerstone of Treatment in Myelofibrosis
Ruben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.
Pacritinib Shows Spleen and Symptom Response in Myelofibrosis With Low Platelets
During a live virtual event, John O. Mascarenhas, MD, discussed the PERSIST-1 and PERSIST-2 trials of pacritinib for patients with myelofibrosis with lower platelet counts.
Reactions to the Latest Data on JAK Inhibition for Myelofibrosis
During a live virtual event, John O. Mascarenhas, MD, discussed with participants the data supporting the use of pacritinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Introducing Pacritinib into Treatment Plans for Myelofibrosis
During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.
When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis